Galderma’s Nemluvio shows itch reduction in 48 hours
Galderma’s dermatology monoclonal antibody (mAb) Nemluvio (nemolizumab) has shown proof of improving symptoms of atopic dermatitis (AD) and prurigo nodularis…
News
Padcev-Keytruda notches another Phase III win in bladder cancer
Hutchmed begins Phase I HMPL-A251 clinical development programme
Northwell Health and START open early-phase cancer trial facility
4DMT’s gene therapy hopeful for cystic fibrosis shows promise in Phase I trial
DBV to make new approval bid for VIASKIN Peanut on Phase III trial
Affibody’s ABY-271 breast cancer trial cleared to progress to next phase
Precision medicine approaches needed in oncology to match evolving SoC
